An kafa shi a cikin 2009, JYMed shine babban mai ba da sabis na peptide CRDMO kuma mai ƙera API mai ƙira a cikin Sin ƙwararre a cikin ƙirar al'ada, haɓaka tsari, wadatar asibiti da kasuwanci na abubuwan peptide. Kamfanin yana ɗaukar kusan 600+ FTEs, tare da ƙungiyar gudanarwa ta asali wacce ta ƙunshi ƙwararru waɗanda sama da shekaru 20 na gogewa a fasahar peptide. JYMed yana aiki da cibiyar R&D guda ɗaya da manyan wuraren samarwa da yawa da yawa, tare da ƙarfin masana'antar peptide mai yawan ton.
A matsayin kamfanin mai da hankali kan abokin ciniki, JYMed yana ba da cikakkiyar haɓaka peptide da dandamali na masana'antu wanda ke goyan bayan shekaru 20 na ƙwarewar R&D da kayan aikin zamani. Muna isar da peptides masu inganci waɗanda suka dace da bukatun kowane abokin ciniki.
JYMed yana ba da babban fayil na sama da 20 peptide APIs, gami da Semaglutide, Tirzepatide, Liraglutide, Degarelix, da Oxytocin. Yawancin waɗannan, irin su Semaglutide da Tirzepatide, sun sami nasarar kammala rajista da kasuwanci.
JYMed yana ba da cikakkiyar dandamali na CDMO mai inganci, yana ba da cikakken sabis na bakan don samfuran peptide da peptide-analog. Wannan ya haɗa da bincike da samar da peptides na warkewa, peptides na dabbobi, da ƙari.
JYMed yana samar da peptides na kwaskwarima masu inganci, albarkatun ƙasa, da samfuran OEM waɗanda suka kama daga bincike zuwa darajar cGMP-duk suna ƙarƙashin kulawar inganci. peptides ɗinmu na roba suna da kima sosai don amincin su, tsabta, da sauƙin gyare-gyare.
JYMed shine masana'antar peptide na Amurka da aka bincikar FDA wanda ya kware a peptides na kwaskwarima, peptide APIs, da peptides na al'ada. Abubuwan da muka fito sun haɗa da Semaglutide, Liraglutide, Tirzepatide, Oxytocin, GHK, GHK-Cu, Acetyl Hexapeptide-8, da ƙari. Don ƙarin koyo, da fatan za a tuntuɓe mu a:
Email: jymed@jymedtech.com











JYMed Peptide yana farin cikin gayyatar ku zuwa Pharmaconex 2025, wanda zai gudana daga Satumba 1-3, 2025, a Cibiyar Baje kolin Masarautar Masar (EIEC) a Alkahira. Rufe filin nuni na murabba'in murabba'in 12,000+, taron zai karbi bakuncin masu baje kolin 350+ kuma ana sa ran zai jawo hankalin masu sana'a 8,000+ ...

JYMed Peptide yana farin cikin gayyatar ku zuwa CPhI Korea 2025, wanda zai gudana daga Agusta 26-28, 2025, a Cibiyar Taron COEX & Nunin a Seoul. Tsawon murabba'in murabba'in mita 15,000, ana sa ran taron zai karbi bakuncin masu baje koli fiye da 450 kuma yana maraba da maziyartan kwararru sama da 10,000. A shekarar 2024...

Muna farin cikin shiga cikin shugabannin masana'antu a CPHI Kudu maso Gabashin Asiya 2025, wanda ke faruwa daga Yuli 16 zuwa 18 a MITEC a Kuala Lumpur. Taron ya zagaya sama da murabba'in murabba'in 15,000 kuma zai ƙunshi masu nunin 400. Fiye da kwararru 8,000 ne ake sa ran za su halarta, tare da tarukan karawa juna sani na 60+ da tarukan f...